Project/Area Number |
10670606
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Neurology
|
Research Institution | TOHO UNIVERSITY |
Principal Investigator |
KAKIUCHI Terutaka TOHO UNIVERSITY SCHOOL OF MEDICINE, PROFESSOR, 医学部, 教授 (40126024)
|
Co-Investigator(Kenkyū-buntansha) |
NAKANO Hideki TOHO UNIVERSITY SCHOOL OF MEDICINE, ASSOCIATE, 医学部, 助手 (30266928)
KURIHARA Teruyuki TOHO UNIVERSITY SCHOOL OF MEDICINE, PROFESSOR, 医学部, 教授 (80098607)
|
Project Period (FY) |
1998 – 1999
|
Project Status |
Completed (Fiscal Year 1999)
|
Budget Amount *help |
¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1998: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
Keywords | Multiple Sclerosis / Encephalomyelitis / EAE / T cell / Homing / plt / Chemokine / SLC / 脳脊髄膜炎 |
Research Abstract |
We have found a mutant mouse strain with DDD background, plt (paucity of lymph node T cells) mouse, in which T cells are unable to migrate into the T cell areas in lymph nodes, Peyer's patches, or spleen white pulp. Antigen-stimulated dendritic cells do not entry into the T cell zones either. These mice lack the expression of secondary lymphoid tissue chemokine (SLC)s, which results from the deletion of SLC gene. We examined the development of experimental allergic encephalomyelitis (EAE) in these mutant mice. When these mice were immunized with myelin basic protein (MBP), EAE developed with a fewer frequency than in the control mice. Even when the MBP-immunized mutant mice developed EAE, the clinical score in these mice was much lower than in the control mice. For further analysis, we established C57BL/6 mice with the deletion of SLC gene, and immunized with MOG35-55 peptide. C57BL/6-plt mice were also resistant to the development of EAE. MBP- or MOG-specific T cells play a critical role to develop EAE. It might be possible that these T cells were not induced in plt mice immunized with MBP or MOG. However, this possibility seems unlikely, since in vivo T cell-priming with a protein antigen was not affected in these mice. These findings suggest that a chemokine is able to control the EAE development. Our findings also raised a possibility that a chemokine might be able to control multiple sclerosis.
|